

Online Submissions: http://www.wjgnet.com/1948-5182office wjh@wjgnet.com doi:10.4254/wjh.v3.i12.300 World J Hepatol 2011 December 27; 3(12): 300-307 ISSN 1948-5182 (online) © 2011 Baishideng. All rights reserved.

REVIEW

## Hepatic osteodystrophy: An important matter for consideration in chronic liver disease

Germán López-Larramona, Alfredo J Lucendo, Sonia González-Castillo, José M Tenias

Germán López-Larramona, Department of Internal Medicine, Hospital General de Tomelloso, 13700 Ciudad Real, Spain

Alfredo J Lucendo, Sonia González-Castillo, Department of Gastroenterology, Hospital General de Tomelloso, 13700 Ciudad Real, Spain

José M Tenias, Research Support Unit, Complejo Hospitalario Mancha Centro, Alcázar de San Juan, 13700 Ciudad Real, Spain Author contributions: López-Larramona G, Lucendo AJ, González-Castillo S and Tenias JM equally contributed to this manuscript.

Correspondence to: Germán López-Larramona, MD, Department of Internal Medicine, Hospital General de Tomelloso, Vereda de Socuéllamos, s/n, 13700 Tomelloso, Ciudad Real, Spain. germll2003@yahoo.es

Telephone: +34-926-525097 Fax: +34-926-525870 Received: February 4, 2011 Revised: September 21, 2011 Accepted: November 7, 2011 Published online: December 27, 2011

### Abstract

Hepatic osteodystrophy (HO) is the generic term defining the group of alterations in bone mineral metabolism found in patients with chronic liver disease. This paper is a global review of HO and its main pathophysiological, epidemiological and therapeutic aspects. Studies examining the most relevant information concerning the prevalence, etiological factors, diagnostic and therapeutic aspects involved in HO were identified by a systematic literature search of the PubMed database. HO generically defines overall alterations in bone mineral density (BMD) (osteoporosis or osteopenia) which appear as a possible complication of chronic liver disease. The origin of HO is multifactorial and its etiology and severity vary in accordance with the underlying liver disease. Its exact prevalence is unknown, but different studies estimate that it could affect from 20% to 50% of patients. The reported mean prevalence of osteoporosis ranges from 13%-60% in chronic cholestasis to 20% in chronic viral hepatitis and 55% in viral cirrhosis. Alcoholic liver disease is not always related to osteopenia. HO has been commonly studied in chronic cholestatic disease (primary biliary cirrhosis and primary sclerosing cholangitis). Several risk factors and pathogenic mechanisms have been associated with the loss of BMD in patients with chronic liver disease. However, little information has been discovered in relationship to most of these mechanisms. **Screening for osteopenia** and osteoporosis is recommended in advanced chronic liver disease. There is a lack of randomized studies assessing specific management for HO.

© 2011 Baishideng. All rights reserved.

Key words: Hepatic osteodystrophy; Liver disease; Osteoporosis; Osteopenia

**Peer reviewers:** Hatim Mohamed Yousif Mudawi, Associate Professor of Medicine, Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Sudan. PO Box 2245, Khartoum, Sudar; Ioannis Diamantis, MD, PhD, Professor, Department of Internal Medicine, University of Athens Medical School, A. Tritsi 26 Gr-15238, Athens, Greece

López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. *World J Hepatol* 2011; 3(12): 300-307 Available from: URL: http://www.wjgnet. com/1948-5182/full/v3/i12/300.htm DOI: http://dx.doi. org/10.4254/wjh.v3.i12.300

#### INTRODUCTION

Hepatic osteodystrophy (HO) is the generic term defining the group of alterations in bone mineral metabolism found in patients with chronic liver disease<sup>[1]</sup>. These individuals have been described as having a higher rate of osteopenia and osteoporosis and the different studies performed in this connection have shown that the rates vary. HO is therefore a common complication throughout the progression of chronic hepatopathy and involves dete-



rioration in quality of life which affects the patient's longterm prognosis<sup>[2]</sup>. Consequently, a detailed bone mineral density (BMD) and bone metabolism evaluation should be performed in all patients with chronic liver disease in order to prevent fractures and chronic pain. This article aims to provide a general review of HO.

### CHRONIC LIVER DISEASE AND ITS ASSOCIATION WITH OSTEOPENIA AND OSTEOPOROSIS

## The prevalence of osteoporosis and fracture risk in patients with chronic liver disease

Metabolic bone disease is a significant disorder which appears in patients with chronic hepatopathy (also known as HO), especially in those affected by chronic cholestasis<sup>[3,4]</sup>. Its etiology is complex and multifactorial and manifests as osteopenia and osteoporosis. This bone disorder must be evaluated and detected early in all patients with chronic liver disease in order to minimize the risk of fractures and improve their clinical progression and quality of life<sup>[5]</sup>. Various studies have been conducted on the prevalence of osteoporosis in these patients and in patients with chronic cholestasis (Table 1). In most of this research, bone density is calculated using a bone densitometry. However, the authors use different methods to analyze mineral density in order to select patients and even have different definitions of osteoporosis<sup>[6-8]</sup>.

Patients with chronic liver disease harbor additional risk factors for developing osteoporosis, such as hypogonadism, vitamin D deficiency, alcohol consumption, chronic steroid treatment and a low body mass index<sup>[9]</sup>. With osteoporosis, the patient is predisposed to suffering bone fractures and increased morbimortality. Vertebral fractures are most frequent in these patients, ranging from 3% to 18%<sup>[10,11]</sup>.

**Cirrhosis:** Different authors consider that the prevalence of osteoporosis in cirrhotic patients is related to the severity of liver disease expressed by the Child-Pugh index<sup>[12,13]</sup>. This prevalence ranges from 20% to 56% and inter-individual variations are observed in relationship to bone density. The fracture rate ranges from 5% to  $20\%^{[14]}$ .

**Chronic cholestatic disease:** A high prevalence of osteoporosis is associated with both primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). This is one of the most widely studied groups of patients with chronic hepatopathy in terms of bone mineral metabolism pathologies. Its prevalence among different groups is estimated to range from 13% to  $60\%^{151}$ .

#### PBC

Various studies have been conducted on the BMD of patients with PBC. The predominant alteration in these patients is osteoporosis and osteomalacia is very rare<sup>[16]</sup>.

Reduction in bone density is related to the severity of cholestatic disease, although not all patients with PBC develop osteoporosis and the rate of bone mass loss varies from one individual to another<sup>[17,18]</sup>.

Other factors linked to osteoporosis in PBC are the time to progression of the disease and the degree of cholestasis, as a reflection of the stage of chronic hepatopathy. Post menopause and malabsorption of calcium in the intestine have also been suggested as predisposing factors in these patients<sup>[19]</sup>.

Generally, research on bone pathology in PBC coincides with indicating cholestasis as an independent risk factor for developing osteoporosis. Nevertheless, studies to see if there was an improvement in BMD following treatment with ursodeoxicolic acid did not show significant changes compared to untreated patients. Regarding this aspect, cirrhosis co-existing with advanced cholestatic disease can significantly contribute to alterations in BMD<sup>[9,20]</sup>.

#### PSC

PSC patients harbor various risk factors for developing osteoporosis: cholestasis, co-existing cirrhosis and corticosteroid treatment in the presence of associated inflammatory bowel disease. Individuals with PSC showed a decrease in the BMD of the lumbar vertebrae compared to healthy controls<sup>[10]</sup>.

**Hemochromatosis:** Certain studies have described a link between hemochromatosis and low BMD by relating co-existing hypogonadism and iron overload with the development of osteoporosis<sup>[21]</sup>. The prevalence of the latter is approximately  $30\%^{[22]}$ .

Alcoholism: Alcoholism is an independent risk factor of the development of osteoporosis and osteoporotic fractures and has been especially studied in male patients. BMD of the lumbar vertebrae in these individuals is lower than in healthy controls<sup>[23]</sup> and the risk of fractures is independent from existing cirrhosis or associated hypogonadism<sup>[24,25]</sup>. Alcohol abuse in women who do not have cirrhosis and hypogonadism does not appear to be linked to osteopenia and osteoporosis<sup>[26]</sup>.

**Non-cholestatic and non-cirrhotic hepatopathy:** The exact prevalence of osteoporosis in patients with chronic hepatopathy but who do not have cirrhosis, cholestasis and hypogonadism is unknown. The approximate prevalence of osteoporosis measured at the lumbar vertebrae in this group of patients ranges from 16% to 50%<sup>[27]</sup> with a fracture rate ranging from 12% to 18%<sup>[28]</sup>.

### PHYSIOPATHOLOGY OF BONE MASS LOSS IN PATIENTS WITH CHRONIC LIVER DISEASE

Bone mass increases from childhood, approximately



reaching maximum levels in one's thirties. From one's forties onwards, it starts to decrease in both genders but with a faster loss in women following the menopause. Peak bone mass is determined by genetic and hormonal factors, type of diet and physical activity. The rate of osteoporosis increases in the elderly as the loss of bone mineral mass is a phenomenon associated with aging.

Bone mass loss occurs as a result of an increase in bone turnover and/or an imbalance in bone remodeling. The latter can be caused by decreased osteogenesis, increased bone resorption or by a combination of both. Certain studies have shown increased bone resorption in the context of chronic liver disease, even in patients without osteoporosis. Other research has shown decreased bone formation<sup>[12,29]</sup>. A study of bone histomorphometric parameters performed on 50 patients with PBC and PSC showed decreased bone formation (osteoblast dysfunction) in men and women and a significant increase in bone resorption due to osteoclast activation, especially in women. According to the authors, the duration of cholestasis or other associated factors seem to be more important that the severity of the disease itself, expressed by levels of serum bilirubin in the development of osteodystrophy<sup>[30]</sup>.

The risk of osteoporotic fracture is determined not only by BMD but also by trabecular architecture, bone geometry, bone turnover and risk factors which are not associated with the skeleton such as postural instability and the risk of falls.

The main risk factors for developing osteoporosis and, therefore, bone fractures in patients with chronic liver disease include: low body mass index (<  $19 \text{ kg/m}^2$ ), excessive alcohol consumption, prolonged steroid treatment (5 mg/d of prednisolone for over 3 mo), sedentary lifestyle, hip fractures in the mother at a young age (< 60 years), hypogonadism and early menopause (under 45 years)<sup>[9]</sup>.

### PATHOGENIC MECHANISMS INVOLVED IN BONE MASS LOSS IN PATIENTS WITH CHRONIC LIVER DISEASE

#### **Genetic factors**

Certain genetic polymorphisms have been described which may play a secondary role in the development of osteoporosis in chronic cholestatic hepatopathy. These include the vitamin D receptor gene, the collagen type 1  $\alpha$  1 gene and insulin-like growth factor (IGF-1) polymorphisms<sup>[31]</sup>.

#### Anomalies of calcium and vitamin D metabolism

Vitamin D is produced by endogenous synthesis in the skin, aided by sunlight, from which cholecalciferol is synthesized (vitamin D<sub>3</sub>). Both cholecalciferol and ergo-calciferol or vitamin D<sub>2</sub> can also be obtained from food. Vitamin D undergoes 25-hydroxylation in the liver tissue, a process which is affected by advanced liver disease.

Vitamin D deficiency is associated with secondary hyperparathyroidism, an increase in bone turnover and accelerated loss of bone mass. Various studies have shown low serum 25-hydroxyvitamin D levels in individuals affected by chronic liver disease, which continue decreasing as cirrhosis develops<sup>[32-34]</sup>. The main factors triggering vitamin D deficiency in chronic hepatopathy are believed to be limited exposure to ultraviolet radiation and nutritional deficiency. Intestinal malabsorption, alterations in the enterohepatic circulation of vitamin D and decreased skin synthesis in individuals with jaundice also contribute to vitamin D deficiency. However, no significant correlation between osteopenia and decreased vitamin D levels has been demonstrated in patients with chronic cholestasis<sup>[35]</sup>.

#### Vitamin K deficiency

Vitamin K is an essential cofactor for osteoblasts to synthesize osteocalcin - bone matrix protein. Vitamin K deficiency contributes to osteopenia in patients with PBC and supplementing it can prevent them from losing bone mass<sup>[36]</sup>.

#### **IGF-1** deficiency

IGF-1 is involved in osteoblast differentiation and proliferation. Low serum levels of IGF-1 were observed in a study with bile duct-ligated rats, suggesting that cholestasis deeply affects its activity<sup>[37]</sup>. Therefore, its deficiency observed in cirrhosis and cholestatic hepatopathies may cause osteoblast dysfunction and osteopenia<sup>[14,15]</sup>.

#### Hyperbilirubinemia

*In vitro* studies on animal models show that the increase in unconjugated bilirubin impairs osteoblast function in a dose-dependent and reversible effect<sup>[38,39]</sup>. The results of research on humans are inconsistent. For some authors, osteopenia progresses at the same rate as jaundice does in patients with PBC and PSC<sup>[40]</sup>, while this correlation is insignificant for others<sup>[41]</sup>.

# Receptor activator of nuclear factor *KB* ligand and osteoprotegerin

The receptor activator of nuclear factor KB ligand/osteoprotegerin (RANKL/OPG) system regulates bone metabolism by modulating osteoclast activity, to the extent that OPG is a factor which inhibits that activity while the RANKL ligand activates it. Various research has shown that the OPG/RANKL ratio is high in patients with chronic liver disease compared to control subjects, which shows that there is ligand consumption that activates osteoclastic activity, and an excess OPG as a compensating mechanism which tries to prevent the loss of bone mass<sup>[42-44]</sup>. Other cytokines involved in the pathogenesis of chronic liver disease such as interleukin (IL)-1, IL-6 and tumor necrosis factor  $\alpha$  can activate this system<sup>[37]</sup>. Additionally, circulating mononuclear cells could have a higher capacity to differentiate into osteoclasts in patients with chronic liver disease and osteopenia<sup>[45]</sup>.

#### Hypogonadism

Hypogonadism associated with chronic hepatopathy has



Table 1	Prevalence of	f osteopenia and	osteoporosis in chronic liver	disease of various etiologies	

Ref.	n	Etiology	Prevalence of osteopenia/ osteoporosis	Pathogenic mechanisms/ associated factors
Goral <i>et al</i> <sup>[14]</sup> , 2010	55	Child A-B-C cirrhosis	Osteoporosis 37%	Increased TNFa and IL-6 levels
		Mixed etiology		Decreased IGF-1 levels
Wariaghli <i>et al</i> <sup>[53]</sup> ,	64	Cirrhosis	Osteoporosis 45.3%	Female sex
2010		Mixed etiology		Cholestasis
				Lower weight and height
Loria <i>et al</i> <sup>[67]</sup> , 2010	35	Cirrhosis	Osteoporosis 14%	Not specified
		Viral and alcoholic	Osteopenia 26%	
George <i>et al</i> <sup>[34]</sup> , 2010	72	Cirrhosis	Low BMD 68%	Low levels of IGF-1
		Viral and alcoholic		
Sokhi <i>et al</i> <sup>[66]</sup> , 2004	104	Cirrhosis	Osteoporosis 11.5%	Child B-C stage and female
		Mixed etiology	Osteopenia 34.6%	female
Gallego-Rojo et al <sup>[12]</sup> ,	32	Viral cirrhosis	Osteoporosis 53%	Child stage
1998				IGF-1 serum levels
Auletta <i>et al</i> <sup>[72]</sup> , 2005	30	Chronic viral hepatitis	Osteoporosis 20%	Chronic hepatopathy per se
			Osteopenia 44%	
Diamond <i>et al</i> <sup>[11]</sup> , 1989	22	Hemochromatosis	Osteoporosis 45%	Hypogonadism
				Low free testosterone levels
Sinigaglia et al <sup>[22]</sup> , 1997	32	Hemochromatosis	Osteoporosis 28%	Cirrhosis and iron overload
Mounach <i>et al</i> <sup>[73]</sup> , 2008	33	Primary biliary cirrhosis	Osteoporosis 51.5%	Low BMI
				Menopausal status
				Duration of liver disease
				Vitamin D deficiency
Lindor <i>et al</i> <sup>[20]</sup> , 1995	88	Primary biliary cirrhosis	Osteoporosis 35%	not specified
Guañabens et al <sup>[74]</sup> ,	20	Primary biliary cirrhosis	Osteoporosis 35%	Duration of liver disease
1990				Post menopause
				Malabsorption of calcium
Angulo <i>et al</i> <sup>[10]</sup> , 1998	81	Primary sclerosing cholangitis	Osteoporosis 17%	Stage of liver disease
				Associated advanced inflammatory bowel disease
Malik <i>et al</i> <sup>[23]</sup> , 2009	57	Alcoholic	Low BMD (z-score $\leq$ -2.0) 17.5%	25-hydroxy-vitamin D deficiency
Kim <i>et al</i> <sup>[24]</sup> , 2003	18	Alcoholic	Osteoporosis 22%	Cumulative alcohol intake
			Osteopenia 50%	
Gonzalez-Calvín	39	Alcoholic	Osteopenia 23%	Cumulative alcohol intake
et al <sup>[25]</sup> , 1993				Impairment of osteoblastic activity by ethanol

BMD: Bone mass density; BMI: Body mass index; IGF-1: Insulin-like growing factor 1; IL-6: Interleukin-6; TNF: Tumoral necrosis factor.

been proposed as a factor which favors the loss of BMD. Low levels of estradiol, luteinizing hormone and folliclestimulating hormone have been observed in postmenopausal women with cirrhosis, with normal testosterone and sex hormone binding globulin<sup>[46]</sup>. However, in males with advanced liver disease, there is an increase in the level of estrogen due to peripheral aromatization, which does not seem to protect against bone mass loss in individuals with alcoholic liver disease<sup>[47]</sup>.

#### Medication

Glucocorticoid-based treatments in autoimmune liver disease and chronic cholestatic liver diseases accelerate the loss of bone mass, although their contribution is difficult to estimate due to the effect of liver disease *per se* on the bone<sup>[48]</sup>. The adverse effect of cholestyramine on the intestinal absorption of vitamin D has also been reported<sup>[15]</sup>.

#### Lifestyle

Alcohol consumption and smoking aggravate osteopenia/osteoporosis, together with a sedentary lifestyle, malnutrition and a low body mass index<sup>[49]</sup>.

### DIAGNOSTIC AND THERAPEUTIC ASPECTS OF OSTEOPENIA AND OSTEOPOROSIS IN CHRONIC LIVER DISEASE

#### Diagnosis of osteopenia and osteoporosis

The main objective for assessing and treating HO is to prevent bone fractures. BMD is measured using dual energy X-ray bone absorptiometry performed on the lumbar vertebrae and femoral neck. The results of the measurement are classified on a scale by the World Health Organization, the *t-score* being the basic parameter for diagnosis. Osteoporosis is therefore defined as a BMD of less than 2.5 standard deviation compared to the normal average score for young adults (*t-score* of less than -2.5). Similarly, osteopenia is defined as having a *t-score* of between -1 and -2.5<sup>[50]</sup>. Prospective studies show how the risk of fractures increases progressively in proportion to the decrease in BMD, with between a two-fold and threefold increase per standard deviation decrease therein<sup>[51]</sup>.

Assessment of all patients with chronic liver disease and suspected osteoporosis should include a hemogram



WJH | www.wjgnet.com

and basic biochemistry, including liver function, phosphocalcium metabolism and gonadal and thyroid profile. A simple X-ray of the dorsal and lumbar vertebrae is indicated if there is a clinical suspicion of spinal fracture as this is an indication for treatment, irrespective of bone density.

During the bone remodeling process, enzymes and non-enzymatic peptides reach the bloodstream and/or are eliminated through urine. Their concentration in blood and urine is related to the total bone turnover rate. These products, or bone turnover markers (BTM), are divided into two groups: resorption markers and formation markers. The main osteosynthesis markers are procollagen type1carboxyterminal propeptide and procollagen type1aminoterminal propeptide, osteocalcin and alkaline phosphatase bone isoenzyme. Noteworthy among the resorption markers are the urinary excretion of deoxypyridinoline, pyridinoline, type 1 collagen amino-terminal telopeptide and hydroxyprolinuria, the latter being less specific. These markers are usually expressed in relationship to the urinary excretion of creatinine.

BTM are higher in patients with osteoporosis and there is an inverse relationship between their levels and BMD. Until now, there has been no particular consensus regarding the most appropriate strategy for their use in clinical practice, although it is thought that they could be useful for monitoring bone mass loss in response to treatment for osteoporosis and for predicting fracture risk. However, this extreme is yet to be verified, because there have been only a few studies with patients suffering from chronic liver disease carried out<sup>[52,53]</sup>. It would seem that BTM levels are influenced by the extent of hepatic fibrosis and by the intrahepatic metabolism of collagen in these individuals which could make it difficult to interpret the results obtained<sup>[9]</sup>.

#### Treatment of osteoporosis in chronic liver disease

There are very few randomized-controlled intervention studies on the prevention of osteoporosis and fractures in chronic liver disease. Most of available data relate to studies performed on patients with PBC<sup>[6-8]</sup> and do not evaluate the effective reduction in fracture rates.

General non-pharmacological measures and specific antiosteoporotic drugs are available to treat HO.

**General measures:** These include lifestyle and nutritional measures aimed at correcting the reversible risk factors, such as alcohol consumption, smoking and making lifestyle changes by introducing regular moderate physical exercise.

Extensive studies have provided no evidence on the effect of calcium and vitamin D in preventing OP and fractures in these patients. Research has been performed on small groups yielding inconsistent BMD results<sup>[16,32,51]</sup>. However, it seems reasonable to recommend supplements by taking a daily dose of 800 UI of vitamin D3 and 1 g of calcium<sup>[9,54]</sup>.

**Specific drugs in the treatment of HO:** Bisphosphonates are powerful anti-resorptive drugs that selectively inhibit osteoclast activity. These agents have been shown to reduce the risk of vertebral and non-vertebral fractures and increase BMD in postmenopausal women with osteoporosis who do not have liver disease<sup>[47]</sup>. They have also been effective in preventing steroid-induced osteoporosis in patients with PBC<sup>[6]</sup>. However, there are no long-term controlled studies developed to evaluate the efficiency of bisphosphonates in fracture-prevention in individuals with chronic liver disease. A study with 80 postmenopausal women with osteoporosis and chronic liver disease secondary to hepatitis virus B and C suggests that a cyclic etidronate treatment could be effective to reduce the incidence of bone fracture<sup>[55]</sup>.

Alendronate improves BMD of patients with PBC<sup>[56,57]</sup>, although it should be used with caution because of potential esophageal side effects<sup>[9]</sup>. Risedronate seems to have a less toxic effect on the esophageal mucosa, which could be useful for treating patients with esophageal varices.

Consequently, bisphosphonates are the main pharmacological agents used in the treatment of HO nowadays, despite the fact that limited data on bisphosphonatestherapy in chronic liver disease are available<sup>[38,58,54]</sup>.

Raloxifene is a selective estrogen receptor modulator. It has positive effects on the lumbar bone mass and femoral neck and reduces vertebral fracture risk in postmenopausal osteoporosis. In a small study of patients with PBC, raloxifene led to significant improvement in lumbar BMD after 1 year of treatment, while no improvement was observed in the femoral neck<sup>[59]</sup>. Evaluation by a bone disease specialist is recommended before using raloxifene in individuals with hepatic disease<sup>[54]</sup>.

Parathyroid hormone (PTH) is a bone-forming drug that is administered subcutaneously in dosages of 20 to 40  $\mu$ g per day, achieving an increase in BMD and a decrease in vertebral fracture risk in postmenopausal osteoporosis. Few data are published on its usefulness in osteoporosis secondary to chronic liver disease. A study in rats with induced biliary cirrhosis showed that intermittent administration of human PTH increases BMD and could be effective to prevent loss of bone mass<sup>[60]</sup>.

Treatment of hypogonadism in patients with chronic liver disease and HO remains controversial. Hormone replacement with testosterone in hypogonadic males without chronic liver disease was efficient and increased BMD<sup>[61]</sup>. Hormone replacement therapy (HRT) with estrogen and progesterone was proposed as a safe treatment for women with chronic hepatopathy, administered either orally or transdermally and sequentially or continuously<sup>[62,63]</sup>. Following the publication of the HERS II<sup>[64]</sup> and WHI<sup>[65]</sup> studies questioning the safety of HRT, its use is currently not recommended. The increased risk of hepatocellular carcinoma related to this treatment should be taken into account by weighing up its benefits and risks and it should be better administered transdermally<sup>[9,37,59]</sup>.



**Orthotopic liver transplantation and bone metabolism:** A high prevalence of low BMD among patients with chronic liver disease just before liver transplantation has been observed. Estimated rates range from 26% to 34% and from 11.5% to 14% for osteopenia and osteoporosis, respectively<sup>[66,67]</sup>.

Immediately after orthotopic liver transplantation (OLT), there is a loss of BMD and fracture risk increases. However, in the long term, osteopenia improves in transplant patients, as shown by a prospective study of patients with PBC and PSC who underwent OLT<sup>[68]</sup>. Thus, liver transplantation is an efficient long-term treatment for osteoporosis in chronic cholestatic liver disease. Biphosphonates have also shown to be useful to avoid bone loss in transplant patients<sup>[69,70]</sup> but there is no evidence to consider one single agent among this group of drugs as first line therapy<sup>[71]</sup>.

#### CONCLUSION

Osteopenia and osteoporosis are important and common complications of chronic liver disease, receiving the generic definition of HO. Their exact prevalence is unknown, ranging between 20% and 50% depending on the series. The development of HO may be due to both increased bone resorption and decreased bone formation. The etiology is multifactorial and can vary in accordance with the origin of the liver disease, having been preferentially studied in chronic cholestatic diseases (PBC and PSC). There are multiple risk factors associated with loss of BMD, the most important being chronic cholestasis and advanced cirrhosis.

Pathogenic mechanisms are diverse and very little is known about some of them: genetic factors, alterations in calcium-vitamin D metabolism, hyperbilirubinemia, vitamin K and IGF-1 deficiency, RANKL-OPG system activity and hypogonadism.

Osteoporosis can result in bone fractures with a harmful effect on morbidity and quality of life. Therefore, an assessment of bone metabolism and risk factors for bone loss and a BMD measurement are recommended in patients with chronic liver disease. An early diagnosis of HO is essential to correct reversible risk factors which predispose to bone mass loss.

Treatment and prevention strategies include general measures, dietary and lifestyle, calcium and vitamin D3 supplementation and bisphosphonates. However, advanced HO is difficult to treat and special care is required to prevent bone loss in individuals with severe hepatic disease. Further research is needed since there are no large randomized controlled trials of intervention in chronic liver disease and osteoporosis. In the same way, there is lack of randomized studies in areas like fracture prevention with available therapeutic agents and potential usefulness of new treatments for osteoporosis.

#### REFERENCES

1 Nakchbandi IA, van der Merwe SW. Current understanding

of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 660-670

- 2 Marignani M, Angeletti S, Capurso G, Cassetta S, Delle Fave G. Bad to the bone: the effects of liver diseases on bone. *Minerva Med* 2004; 95: 489-505
- 3 Rouillard S, Lane NE. Hepatic osteodystrophy. *Hepatology* 2001; 33: 301-307
- 4 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. *Clin Rev Allergy Immunol* 2005; 28: 147-157
- 5 Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr Clin Pract 2006; 21: 273-278
- 6 Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26: 325-330
- 7 Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. *Gastroenterology* 1982; 83: 97-102
- 8 **Epstein O**, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. *Am J Clin Nutr* 1982; **36**: 426-430
- 9 Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. *Gut* 2002; **50** Suppl 1: i1-i9
- 10 Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998; 29: 729-735
- 11 Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110: 430-436
- 12 Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. *Hepatology* 1998; 28: 695-699
- 13 Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. *Calcif Tissue Int* 1997; 60: 148-154
- 14 Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol 2010; 16: 1639-1643
- 15 Gasser RW. Cholestasis and metabolic bone disease a clinical review. Wien Med Wochenschr 2008; 158: 553-557
- 16 Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep 2011; 13: 40-48
- 17 Van Berkum FN, Beukers R, Birkenhäger JC, Kooij PP, Schalm SW, Pols HA. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. *Gastroenterology* 1990; **99**: 1134-1139
- 18 Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Biffi A, Zuin M, Podda M. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. *Hepatology* 1994; 20: 633-637
- 19 Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. *Clin Liver Dis* 2008; 12: 407-424; x
- 20 Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? *Hepatology* 1995; 21: 389-392
- 21 Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. *J Bone Miner Res* 1991; 6: 39-43
- 22 Sinigaglia L, Fargion S, Fracanzani AL, Binelli L, Battafarano

WJH www.wjgnet.com

N, Varenna M, Piperno A, Fiorelli G. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. *J Rheumatol* 1997; **24**: 1809-1813

- 23 Malik P, Gasser RW, Kemmler G, Moncayo R, Finkenstedt G, Kurz M, Fleischhacker WW. Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. *Alcohol Clin Exp Res* 2009; **33**: 375-381
- 24 Kim MJ, Shim MS, Kim MK, Lee Y, Shin YG, Chung CH, Kwon SO. Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. *Korean J Intern Med* 2003; 18: 174-180
- 25 Gonzalez-Calvín JL, Garcia-Sanchez A, Bellot V, Muñoz-Torres M, Raya-Alvarez E, Salvatierra-Rios D. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. *Alcohol Alcohol* 1993; 28: 571-579
- 26 Laitinen K, Kärkkäinen M, Lalla M, Lamberg-Allardt C, Tunninen R, Tähtelä R, Välimäki M. Is alcohol an osteoporosis-inducing agent for young and middle-aged women? *Metabolism* 1993; 42: 875-881
- 27 Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J. Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection. *World J Gastroenterol* 2005; 11: 1843-1847
- 28 Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. *Gut* 1990; **31**: 82-87
- 29 Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. *Calcif Tissue Int* 1999; 64: 295-300
- 30 Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. *Hepatology* 2002; 36: 895-903
- 31 Parés A, Guañabens N, Rodés J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 2005; 17: 311-315
- 32 **Crawford BA**, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. *Nat Clin Pract Gastroenterol Hepatol* 2006; **3**: 689-699
- 33 Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. *Dig Dis Sci* 2010; 55: 2624-2628
- 34 George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009; 15: 3516-3522
- 35 Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol 2003; **38**: 856-865
- 36 Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Kubo S. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. *J Hepatol* 2001; 35: 543-545
- 37 Pereira FA, Facincani I, Jorgetti V, Ramalho LN, Volpon JB, Dos Reis LM, de Paula FJ. Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease. *Calcif Tissue Int* 2009; 85: 75-83
- 38 Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. *J Clin Invest* 1995; 95: 2581-2586
- 39 Weinreb M, Pollak RD, Ackerman Z. Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis. J Hepatol 2004; 40: 385-390
- 40 Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. *J Hepatol* 2001; 35: 316-323

- 41 Smith DL, Shire NJ, Watts NB, Schmitter T, Szabo G, Zucker SD. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J Clin Densitom 2006; 9: 105-113
- 42 Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005; **43**: 973-983
- 43 **Szalay F**, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. *J Hepatol* 2003; **38**: 395-400
- 44 González-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibañez JJ. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab 2009; 94: 4844-4850
- 45 **Olivier BJ**, Schoenmaker T, Mebius RE, Everts V, Mulder CJ, van Nieuwkerk KM, de Vries TJ, van der Merwe SW. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. *Hepatology* 2008; **47**: 259-267
- 46 Bell H, Raknerud N, Falch JA, Haug E. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. *Eur J Endocrinol* 1995; 132: 444-449
- 47 García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. *Alcohol Alcohol* 2006; **41**: 261-266
- 48 Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. *Cochrane Database Syst Rev* 2005; CD003778
- 49 Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. *Clin Liver Dis* 2005; **9**: 747-766, viii
- 50 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; **843**: 1-129
- 51 Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. *Am J Gastroenterol* 1994; 89: 47-50
- 52 Yenice N, Gümrah M, Mehtap O, Kozan A, Türkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. *Turk J Gastroenterol* 2006; **17**: 260-266
- 53 Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A. Osteoporosis in chronic liver disease: a case-control study. *Rheumatol Int* 2010; 30: 893-899
- 54 Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. *Gastroenterology* 2003; 125: 941-966
- 55 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Ikeda K, Kumada H. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 2008; 80: 1302-1307
- 56 Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, Monegal A, Martínez de Osaba MJ, Roca M, Peris P, Rodés J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2268-2274
- 57 Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebocontrolled trial. *Hepatology* 2005; 42: 762-771
- 58 Collier J. Bone disorders in chronic liver disease. *Hepatology* 2007; 46: 1271-1278
- 59 Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. *Liver Int*



2005; 25: 117-121

- 60 Dresner-Pollak R, Gabet Y, Steimatzky A, Hamdani G, Bab I, Ackerman Z, Weinreb M. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. *Gastroenterology* 2008; 134: 259-267
- 61 Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Longterm substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. *Clin Endocrinol* (Oxf) 1999; 50: 629-635
- 62 O'Donohue J, Williams R. Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol 1997; 104: 1-3
- 63 Selby PL, Peacock M. The effect of transdermal oestrogen on bone, calcium-regulating hormones and liver in postmenopausal women. *Clin Endocrinol* (Oxf) 1986; **25**: 543-547
- 64 American College of Obstetricians and Gynecologists. Statement on results of the HERS II trial on hormone replacement therapy. *Ginecol Obstet Mex* 2002; **70**: 406-408
- 65 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002; 288: 321-333
- 66 Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. *Liver Transpl* 2004; 10: 648-653
- 67 Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, Di Menna S, Pirazzi C, Corradini SG, Mennini G, Rossi M, Berloco P, Merli M. Bone disorders in patients with

chronic liver disease awaiting liver transplantation. *Transplant Proc* 2010; **42**: 1191-1193

- 68 **Guichelaar MM**, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. *Liver Transpl* 2006; **12**: 1390-1402
- 69 Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. *Liver Transpl* 2005; **11**: 960-966
- 70 Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 239-248
- 71 Maalouf NM, Sakhaee K. Treatment of Osteoporosis in Patients with Chronic Liver Disease and in Liver Transplant Recipients. *Curr Treat Options Gastroenterol* 2006; 9: 456-463
- 72 Auletta M, Nuzzo V, Esposito A, Antoniello S, Fonderico F, Lupoli G. Osteoporosis in men: a study in patients affected by chronic non-advanced liver disease. *Clin Cases Miner Bone Metab* 2005; 2: 25-28
- 73 **Mounach A**, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A. Primary biliary cirrhosis and osteoporosis: a case-control study. *J Bone Miner Metab* 2008; **26**: 379-384
- 74 Guañabens N, Parés A, Mariñoso L, Brancós MA, Piera C, Serrano S, Rivera F, Rodés J. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. *Am J Gastroenterol* 1990; 85: 1356-1362

S-Editor Zhang SJ L-Editor Roemmele A E-Editor Zheng XM

